

Title	Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study
Authors	Osmanov, Ismail M.;Spiridonova, Ekaterina;Bobkova, Polina;Gamirova, Aysylu;Shikhaleva, Anastasia;Andreeva, Margarita;Blyuss, Oleg;El-Taravi, Yasmin;DunnGalvin, Audrey;Comberiati, Pasquale;Peroni, Diego G.;Apfelbacher, Christian;Genuneit, Jon;Mazankova, Lyudmila;Miroshina, Alexandra;Chistyakova, Evgeniya;Samitova, Elmira;Borzakova, Svetlana;Bondarenko, Elena;Korsunskiy, Anatoliy A.;Konova, Irina;Wulf Hanson, Sarah;Carson, Gail;Sigfrid, Louise;Scott, Janet T.;Greenhawt, Matthew;Whittaker, Elizabeth A.;Garralda, Elena;Swann, Olivia V.;Buonsenso, Danilo;Nicholls, Dasha E.;Simpson, Frances;Jones, Christina;Semple, Malcolm G.;Warner, John O.;Vos, Theo;Olliaro, Piero;Munblit, Daniel
Publication date	2022-02
Original Citation	Osmanov, I. M., Spiridonova, E., Bobkova, P., Gamirova, A., Shikhaleva, A.,Andreeva, M., Blyuss, O., El-Taravi, Y., DunnGalvin, A., Comberiati, P., Peroni, D. G., Apfelbacher, C., Genuneit, J., Mazankova, L., Miroshina, A., Chistyakova, E., Samitova, E., Borzakova, S., Bondarenko, E., Korsunskiy, A. A., Konova, I., Wulf Hanson, S., Carson, G., Sigfrid, L., Scott, J. T., Greenhawt, M., Whittaker, E. A., Garralda, E., Swann, O. V., Buonsenso, D., Nicholls, D. E., Simpson, F., Jones, C., Semple, M. G., Warner, J. O., Vos, T., Olliaro, P., Munblit, D. and the Sechenov StopCOVID Research Team (2022) 'Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study', European Respiratory Journal, 59(2), 2101341 (11pp). doi: 10.1183/13993003.01341-2021
Type of publication	Article (peer-reviewed)
Link to publisher's version	10.1183/13993003.01341-2021
Rights	© 2022, the authors. This version is distributed under the terms of the Creative Commons Attribution Licence 4.0. - https://creativecommons.org/licenses/by/4.0/

Download date	2026-08-08 14:30:56
Item downloaded from	https://hdl.handle.net/10468/13623





SHAREABLE PDF

Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study

Ismail M. Osmanov^{1,2,29}, Ekaterina Spiridonova^{3,29}, Polina Bobkova^{3,29}, Aysylu Gamirova^{3,29}, Anastasia Shikhaleva^{3,29}, Margarita Andreeva^{3,29}, Oleg Blyuss^{3,4,29}, Yasmin El-Taravi³, Audrey DunnGalvin^{3,5}, Pasquale Comberiati⁶, Diego G. Peroni⁶, Christian Apfelbacher⁷, Jon Genuneit⁸, Lyudmila Mazankova⁹, Alexandra Miroshina¹, Evgeniya Chistyakova¹⁰, Elmira Samitova^{1,9}, Svetlana Borzakova^{2,11}, Elena Bondarenko³, Anatoliy A. Korsunskiy³, Irina Konova¹, Sarah Wulf Hanson¹², Gail Carson¹³, Louise Sigfrid¹³, Janet T. Scott¹⁴, Matthew Greenhawt¹⁵, Elizabeth A. Whittaker¹⁶, Elena Garralda¹⁷, Olivia V. Swann^{18,19}, Danilo Buonsenso^{19,20,21,22}, Dasha E. Nicholls¹⁷, Frances Simpson²³, Christina Jones²⁴, Malcolm G. Semple^{25,26}, John O. Warner²⁷, Theo Vos¹², Piero Olliaro¹³, Daniel Munblit^{3,27,28,29} and the Sechenov StopCOVID Research Team³⁰

¹Z.A. Bashlyaeva Children's Municipal Clinical Hospital, Moscow, Russia. ²Pirogov Russian National Research Medical University, Moscow, Russia. ³Dept of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia. ⁴School of Physics, Astronomy and Mathematics, University of Hertfordshire, Hatfield, UK. ⁵School of Applied Psychology, University College Cork, Cork City, Ireland. ⁶Dept of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy. ⁷Institute of Social Medicine and Health Systems Research, Faculty of Medicine, Otto von Guericke University Magdeburg, Magdeburg, Germany. ⁸Pediatric Epidemiology, Dept of Pediatrics, Medical Faculty, Leipzig University, Leipzig, Germany. ⁹Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation, Moscow, Russia. ¹⁰Dept of Paediatrics and Paediatric Rheumatology, Institute of Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia. ¹¹Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Dept, Moscow, Russia. ¹²Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA. ¹³ISARIC Global Support Centre, Nuffield Dept of Medicine, University of Oxford, Oxford, UK. ¹⁴MRC-University of Glasgow Centre for Virus Research, Glasgow, UK. ¹⁵Dept of Pediatrics, Section of Allergy/Immunology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA. ¹⁶Paediatric Infectious Diseases, Imperial College Healthcare NHS Trust, London, UK. ¹⁷Division of Psychiatry, Imperial College London, London, UK. ¹⁸Dept of Child Life and Health, University of Edinburgh, Edinburgh, UK. ¹⁹Paediatric Infectious Diseases, Royal Hospital for Children, Glasgow, UK. ²⁰Dept of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. ²¹Dipartimento di Scienze Biotechnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy. ²²Center for Global Health Research and Studies, Università Cattolica del Sacro Cuore, Rome, Italy. ²³Coventry University, Coventry, UK. ²⁴School of Psychology, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK. ²⁵Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK. ²⁶Dept of Respiratory Medicine, Alder Hey Children's Hospital, Liverpool, UK. ²⁷Inflammation, Repair and Development Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK. ²⁸Research and Clinical Center for Neuropsychiatry, Moscow, Russia. ²⁹These authors contributed equally to this article. ³⁰A list of members of the Sechenov StopCOVID Research Team can be found in the Acknowledgements section.

Corresponding author: Daniel Munblit (daniel.munblit08@imperial.ac.uk)



Shareable abstract (@ERSpublications)

A quarter of children experienced persistent symptoms months after COVID-19 infection, with almost one in 10 experiencing multisystem involvement. Older age and allergic diseases were associated with higher risk of persistent symptoms at follow-up. <https://bit.ly/3vqeEmZ>

Cite this article as: Osmanov IM, Spiridonova E, Bobkova P, *et al.* Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study. *Eur Respir J* 2022; 59: 2101341 [DOI: 10.1183/13993003.01341-2021].

This single-page version can be shared freely online.

Abstract

Copyright ©The authors 2022.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

This article has an editorial commentary:

<https://doi.org/10.1183/13993003.02245-2021>

Received: 10 May 2021
Accepted: 9 June 2021



Background The long-term sequelae of coronavirus disease 2019 (COVID-19) in children remain poorly characterised. This study aimed to assess long-term outcomes in children previously hospitalised with COVID-19 and associated risk factors.

Methods This is a prospective cohort study of children (≤ 18 years old) admitted to hospital with confirmed COVID-19. Children admitted between 2 April 2020 and 26 August 2020 were included. Telephone interviews used the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) COVID-19 Health and Wellbeing Follow-up Survey for Children. Persistent symptoms (>5 months) were further categorised by system(s) involved.

Results 518 out of 853 (61%) eligible children were available for the follow-up assessment and included in the study. Median (interquartile range (IQR)) age was 10.4 (3–15.2) years and 270 (52.1%) were girls. Median (IQR) follow-up since hospital discharge was 256 (223–271) days. At the time of the follow-up interview 126 (24.3%) participants reported persistent symptoms, among which fatigue (53, 10.7%), sleep disturbance (36, 6.9%) and sensory problems (29, 5.6%) were the most common. Multiple symptoms were experienced by 44 (8.4%) participants. Risk factors for persistent symptoms were: older age “6–11 years” (OR 2.74, 95% CI 1.37–5.75) and “12–18 years” (OR 2.68, 95% CI 1.41–5.4), and a history of allergic diseases (OR 1.67, 95% CI 1.04–2.67).

Conclusions A quarter of children experienced persistent symptoms months after hospitalisation with acute COVID-19 infection, with almost one in 10 experiencing multisystem involvement. Older age and allergic diseases were associated with higher risk of persistent symptoms at follow-up.